Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20 million that will see the company build out an oncology drug discovery pipeline derived from its AI proteomics platform.

Seamless Therapeutics GmbH raised $12.5 million in seed financing to take forward a novel gene editing technology based on reprogramming recombinase enzymes.

Aldena Therapeutics Inc. secured $30 million in seed funding from founding investor Medicxi to bring siRNA-based drugs to the skin.

Newco Relation Therapeutics Ltd. is showing its colors after raising $25 million in a seed round to work on integrating single cell transcriptomics, functional genomics and machine learning – and cut through previously undecipherable combinatorial space – to find and validate drug targets in the non-coding genome.

Resalis Therapeutics Srl has completed a seed financing round of €10 million (US$10.6 million) to establish a noncoding RNA (ncRNA)-based...

Resalis Therapeutics Srl closed a €10 million (US$10.6 million) seed round to progress toward the clinic a micro-RNA (miR) inhibitor in development for metabolic disease indications. Riccardo Panella, chief scientific officer and founder, identified the potential of a particular miR species, miR-22, as a target for metabolic syndrome while conducting studies on its potential role in oncology while at Harvard Medical School and Beth Israel Deaconess Medical Center.

Previa Medical SA will begin clinical trials later this year of its artificial intelligence software designed for early detection of sepsis after it raised €2.1 million (US $2.2 million) in seed funds.

Vevo Therapeutics Inc. raised $12 million in an over-subscribed seed round to build out an in vivo single-cell screening platform, which will enable it to interrogate simultaneously the effects of small molecule drug leads on multiple cancer cell lines.